Animal study examines the efficacy of nano-curcumin and nano-chromium in reducing diabetic nerve damage, suggesting potential treatments.
This study aimed to investigate how nano curcumin (Nano-Cur) or nano-chromium chloride (Nano-CrCl) in comparison with metformin (Met), can reduce diabetic neuropathy caused by streptozotocin (STZ) in rats. Seventy Wistar albino male rats were randomly divided into seven groups (ten rats/group): control; STZ-induced diabetes; diabetic rats receiving daily oral doses of Nano-Cur, Cur, Nano-CrCl, CrCl, and Met. The present results show that all treated groups significantly alleviated diabetic neuropathy by restoring serum insulin and glucose levels, enhancing cerebral antioxidant activities and activating IR/PI3K/AKT, normalizing neurotransmitters, decreasing oxidative stress markers (MDA), and reducing inflammatory biomarkers and pyroptotic biomarkers. At the molecular level, the levels of GSK3B, JAK-2, STAT-3, AMPK, and BACE1 were significantly downregulated in all treated diabetic groups compared to the diabetic group, especially Nano-Cur and Met. However, Cur, Nano-CrCl, and CrCl did not cause any significant (p > 0.05) alteration in ACh levels compared to the diabetic group. Additionally, the Nano-Cur, Cur, and Met groups exhibited a marked increase in miRNA-223-3p and miRNA-124 levels, whereas Nano-CrCl and CrCl showed no significant changes in these miRNAs when compared to the diabetic group.
No takes yet. Share an insight, caveat, or question.
Elsayed et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: